摘要
目的:观察表柔比星(EPI)、吉西他滨(GEM)序贯膀胱灌注辅助手术治疗非肌层浸润性膀胱癌的临床效果。方法:非肌层浸润性膀胱癌患者118例,均行经尿道膀胱肿瘤切除术(TUR-BT)。术后分别行EPI(EPI组,40例)、GEM(GEM组,36例)和EPI、GEM序贯(序贯组,42例)膀胱灌注治疗,观察三组膀胱癌复发、进展和不良反应情况。结果:全部病例随访二年,序贯组膀胱癌复发率低于EPI组和GEM组(P均<0.05),EPI与GEM组复发率无明显差异。各组膀胱癌进展率无明显差异(P均>0.05)。EPI组、GEM组、序贯组分别有3、3、4例出现轻度膀胱刺激症状,无其他不良反应。结论:EPI、GEM序贯膀胱灌注辅助手术治疗非肌层浸润性膀胱癌可降低术后二年内复发率,但不能改变膀胱癌的进展。
Objective：To observe the clinical effect of sequential intravesical perfusion of epirubicin with gemcitabine assisting surgical treatment of the non-muscle invasive bladder cancer.Methods：Total of 118 patients with non-muscle invasive bladder cancer.After the TUR-BT operation,underwent intravesical perfusion with drug of EPI（40 patients） or GEM（36 patients）or sequential perfusion（42 patients）.Results：All cases were followed up for two years,the recurrence rate of sequential group was lower than that of EPI group and GEM group（P〈0.05）,and there was no obvious difference between EPI group and GEM group（P〈0.05）.The progress rate in each group had no obvious difference（P〈0.05）.In each group there were 3,3,4 patients with the symptom of mild symptoms bladder irritation,no other adverse reactions.Conclusion：Sequential intravesical perfusion of gemcitabine with epirubicin assisting surgical treatment of the non-muscle invasive bladder cancer can reduce the recurrence rate within two years after operation,but can＇t change the progress of bladder cancer.
出处
《现代肿瘤医学》
CAS
2012年第11期2328-2330,共3页
Journal of Modern Oncology
基金
辽宁省博士科研启动基金项目(编号:20091118)
关键词
表浅性膀胱癌
表柔比星
吉西他滨
序贯膀胱灌注
superficial bladder cancer
epirubicin
gemcitabine
sequential intravesical perfusion
